Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | LPO | P22079 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2196792 | 0.99 | MAPT (0.40) | MAPTTP53SIGMAR1LMNAHRH3 | |
| SCHEMBL2194293 | 0.98 | MAPT (0.39) | MAPTTP53SIGMAR1LMNAHRH3 | |
| SCHEMBL2192592 | 0.98 | MAPT (0.39) | MAPTTP53SIGMAR1LMNAHRH3 | |
| SCHEMBL2195709 | 0.96 | MAPT (0.41) | MAPTTP53SIGMAR1LMNAHRH3 | |
| SCHEMBL2195198 | 0.87 | SIGMAR1 (0.40) | MAPTTP53SIGMAR1LMNAHRH3 | |
| SCHEMBL2195855 | 0.86 | LPO (0.54) | MAPTTP53SIGMAR1LMNAHRH3 | |
| SCHEMBL2195245 | 0.86 | SIGMAR1 (0.39) | MAPTTP53SIGMAR1LMNAHRH3 | |
| SCHEMBL2194561 | 0.85 | LPO (0.53) | MAPTTP53SIGMAR1LMNAHRH3 | |
| SCHEMBL2192101 | 0.85 | SIGMAR1 (0.45) | MAPTSIGMAR1LMNAALDH1A1GAA | |
| SCHEMBL2194325 | 0.85 | LPO (0.52) | MAPTTP53SIGMAR1LMNAHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172199-A1 | PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-14 | — | — | US | claimed |
| US-20110172199-A1 | PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172199-A1 | PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SCO2, C3AR1, IDH1 | MAPT 4712/4885TP53 1327/4885SIGMAR1 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.